{"id":746030,"date":"2019-05-31T05:45:00","date_gmt":"2019-05-31T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/"},"modified":"2025-05-12T08:58:05","modified_gmt":"2025-05-12T12:58:05","slug":"mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/","title":{"rendered":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial"},"content":{"rendered":"<p class=\"bwalignc\">       Survival Benefit Now Observed with KEYTRUDA in Combination with        Chemotherapy in All Patient Populations (Regardless of PD-L1 Expression)        and with KEYTRUDA Monotherapy in Patients Whose Tumors Expressed PD-L1        at CPS \u22651     <\/p>\n<p class=\"bwalignc\">       Data Presented Today at 2019 ASCO Annual Meeting     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of the final analysis of the pivotal<br \/>\n      Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck\u2019s anti-PD-1<br \/>\n      therapy, as monotherapy and in combination with chemotherapy, for the<br \/>\n      first-line treatment of patients with recurrent or metastatic head and<br \/>\n      neck squamous cell carcinoma (HNSCC) at the 2019 American Society of<br \/>\n      Clinical Oncology (ASCO) Annual Meeting (Abstract #6000). Data include<br \/>\n      the first-time presentation of certain overall survival (OS) hypotheses<br \/>\n      from the KEYTRUDA in combination with chemotherapy study arm based on<br \/>\n      PD-L1 expression and the KEYTRUDA monotherapy study arm in the total<br \/>\n      patient population. Results of an interim analysis were presented at the<br \/>\n      European Society for Medical Oncology (ESMO) 2018 Congress and<br \/>\n      demonstrated superior OS outcomes for KEYTRUDA in combination with<br \/>\n      chemotherapy in the total population and KEYTRUDA monotherapy in<br \/>\n      patients whose tumors expressed PD-L1 with Combined Positive Score (CPS)<br \/>\n      \u226520 and CPS \u22651 compared with the EXTREME regimen, the current standard<br \/>\n      of care.\n    <\/p>\n<p>\n      \u201cIt is exciting to see the full results from this trial, which is the<br \/>\n      first study to show superior overall survival over the current standard<br \/>\n      of care known as the EXTREME regimen,\u201d said Dr. Danny Rischin, director<br \/>\n      of the department of medical oncology, Peter MacCallum Cancer Centre,<br \/>\n      Melbourne, Australia. \u201cPatients with recurrent or metastatic head and<br \/>\n      neck cancer have a poor prognosis with limited treatment options. These<br \/>\n      findings underscore the potential of KEYTRUDA monotherapy and in<br \/>\n      combination with platinum-based chemotherapy to become important new<br \/>\n      treatment options.\u201d\n    <\/p>\n<p>\n      The new findings presented today from the final analysis showed that<br \/>\n      KEYTRUDA in combination with chemotherapy (carboplatin or cisplatin plus<br \/>\n      5-FU) reduced the risk of death by 40% in patients whose tumors<br \/>\n      expressed PD-L1 with CPS\u226520, demonstrating significantly longer OS (14.7<br \/>\n      months [95% CI, 10.3-19.3]) compared with the EXTREME regimen (cetuximab<br \/>\n      with carboplatin or cisplatin plus 5-fluorouracil [5-FU]), the current<br \/>\n      standard of care (11.0 months [95% CI, 9.2-13.0]) (HR=0.60 [95% CI,<br \/>\n      0.45-0.82]; p=0.0004). For the dual primary endpoint of progression-free<br \/>\n      survival (PFS), statistical significance was not achieved for KEYTRUDA<br \/>\n      in combination with chemotherapy in the CPS\u226520 population compared with<br \/>\n      the EXTREME regimen (HR=0.73 [95% CI, 0.55-.97]; p=0.0162). New findings<br \/>\n      for the CPS \u22651 population showed KEYTRUDA in combination with<br \/>\n      chemotherapy reduced the risk of death by 35% in these patients, with<br \/>\n      significantly longer OS (13.6 months [95% CI, 10.7-15.5]) compared with<br \/>\n      the EXTREME regimen (10.4 months [95% CI, 9.1-11.7]) (HR=0.65 [95% CI,<br \/>\n      0.53-0.80]; p&lt;0.0001). Per the sequential testing strategy, superiority<br \/>\n      for PFS was not tested in this population (HR=0.82 [95% CI, 0.67-1.00]).<br \/>\n      Results for OS with KEYTRUDA monotherapy in the total population were<br \/>\n      consistent with the previously presented interim analysis, where<br \/>\n      non-inferiority was demonstrated (HR=0.83 [95% CI, 0.70-0.99];<br \/>\n      p=0.0199), with a median OS of 11.5 months (95% CI, 10.3-13.4) for<br \/>\n      KEYTRUDA monotherapy in the total population compared with 10.7 months<br \/>\n      (95% CI, 9.3-11.7) for the EXTREME regimen. There was no difference in<br \/>\n      PFS between KEYTRUDA monotherapy in the total population and the EXTREME<br \/>\n      regimen (HR=1.34 [95% CI, 1.13-1.59]).\n    <\/p>\n<p>\n      \u201cAs a company, Merck is committed to advancing research in this<br \/>\n      challenging treatment setting through our expansive head and neck cancer<br \/>\n      clinical research program,\u201d said Dr. Jonathan Cheng, vice president,<br \/>\n      clinical research, Merck Research Laboratories. \u201cThe full data from<br \/>\n      KEYNOTE-048 illustrate the impact of KEYTRUDA as monotherapy and in<br \/>\n      combination with chemotherapy as potential new first-line treatment<br \/>\n      options for patients with recurrent or metastatic head and neck squamous<br \/>\n      cell carcinoma. We would like to sincerely thank the patients and<br \/>\n      investigators for their involvement in KEYNOTE-048.\u201d\n    <\/p>\n<p>\n      As previously announced, the U.S. Food and Drug Administration (FDA) has<br \/>\n      granted priority review for a new supplemental Biologics License<br \/>\n      Application (sBLA) seeking approval for KEYTRUDA as monotherapy or in<br \/>\n      combination with platinum and 5-FU chemotherapy for the first-line<br \/>\n      treatment of patients with recurrent or metastatic HNSCC based in part<br \/>\n      on data from the second interim analysis of KEYNOTE-048. The FDA has set<br \/>\n      a Prescription Drug User Fee Act (PDUFA), or target action, date of June<br \/>\n      10, 2019.\n    <\/p>\n<p>\n      <b>Study Design and Additional Data from KEYNOTE-048 (Abstract #6000)<\/b>\n    <\/p>\n<p>\n      KEYNOTE-048, a randomized, open-label Phase 3 trial (ClinicalTrials.gov,<br \/>\n      NCT02358031), evaluated KEYTRUDA in combination with chemotherapy or<br \/>\n      KEYTRUDA monotherapy, compared with the EXTREME regimen, as first-line<br \/>\n      treatment in patients with recurrent or metastatic HNSCC. The dual<br \/>\n      primary endpoints were OS and PFS. The secondary endpoints were PFS (at<br \/>\n      six months and 12 months), objective response rate (ORR) and time to<br \/>\n      deterioration in the Quality of Life Global Health Status\/Quality of<br \/>\n      Life Scales of the European Organization for Research and Treatment of<br \/>\n      Cancer (EORTC) Quality of Life Questionnaire and Safety. Duration of<br \/>\n      response (DOR) was evaluated as part of a pre-specified exploratory<br \/>\n      analysis. The primary and secondary endpoints, as well as exploratory<br \/>\n      DOR analysis, were evaluated in patients whose tumors expressed PD-L1<br \/>\n      (CPS \u226520 and CPS \u22651) and in the total population, based on a fixed<br \/>\n      sequential testing strategy. Data cutoff for the final analysis was Feb.<br \/>\n      25, 2019; data cutoff for the previously presented second interim<br \/>\n      analysis was June 13, 2018. Details of the OS benefit observed at the<br \/>\n      final analysis are below:\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\" colspan=\"5\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n<p class=\"bwcellpmargin\">\n            <b>Summary of Overall Survival<\/b>\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          Population (number of patients with event)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          Final Analysis Hazard Ratio (95% CI)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"5\">\n          KEYTRUDA Monotherapy\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          PD-L1 CPS \u226520 (n=133) vs. EXTREME (n=122)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          0.58 (0.44-0.78)<sup>b<\/sup>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          PD-L1 CPS \u22651 (n=257) vs. EXTREME (n=255)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          0.74 (0.61-0.90)<sup>b<\/sup>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          Total Population (n=301) vs. EXTREME (n=300)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          0.83 (0.70-0.99); p=0.0199<sup>c<\/sup>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\" colspan=\"5\">\n<p class=\"bwcellpmargin\">\n            KEYTRUDA in Combination with<br \/>Chemotherapy\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          PD-L1 CPS \u226520 (n=126) vs. EXTREME (n=110)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          0.60 (0.45\u20130.82); p=0.0004<sup>a<\/sup>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          PD-L1 CPS \u22651 (n=242) vs. EXTREME (n=235)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          0.65 (0.53\u20130.80); p&lt;0.0001<sup>a<\/sup>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          Total Population (n=281) vs. EXTREME (n=278)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          0.72 (0.60-0.87)<sup>b<\/sup>\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignr\">\n          <sup>a<\/sup>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Superiority demonstrated.\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignr\">\n          <sup>b<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          No new statistical testing performed because population previously<br \/>\n          demonstrated superiority at interim analysis.\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignr\">\n          <sup>c<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Superiority not demonstrated.\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      The secondary endpoint of ORR was 42.9% for KEYTRUDA in combination with<br \/>\n      chemotherapy in patients whose tumors expressed PD-L1 with CPS \u226520<br \/>\n      compared with 38.2% for the EXTREME regimen. The ORR was 36.4% in<br \/>\n      patients whose tumors expressed PD-L1 with CPS \u22651 for KEYTRUDA in<br \/>\n      combination with chemotherapy compared with 35.7% for the EXTREME<br \/>\n      regimen. The median DOR was 7.1 months (range, 2.1+ to 39.0+) for<br \/>\n      KEYTRUDA in combination with chemotherapy in patients whose tumors<br \/>\n      expressed PD-L1 with CPS \u226520 compared with 4.2 months (range, 1.2+ to<br \/>\n      31.5+) for the EXTREME regimen. The median DOR was 6.7 months (range,<br \/>\n      1.6+ to 39.0+) for KEYTRUDA in combination with chemotherapy in patients<br \/>\n      whose tumors expressed PD-L1 with CPS \u22651 compared with 4.3 months<br \/>\n      (range, 1.2+ to 31.5+) for the EXTREME regimen.\n    <\/p>\n<p>\n      In the KEYTRUDA monotherapy arm, an analysis of the total patient<br \/>\n      population showed an ORR of 16.9% compared with 36.0% for the EXTREME<br \/>\n      regimen; the median DOR was 22.6 months (range, 1.5+ to 43.0+) compared<br \/>\n      with 4.5 months (range, 1.2+ to 38.7+) for the EXTREME regimen.\n    <\/p>\n<p>\n      As previously reported, there were no new safety concerns identified<br \/>\n      with the use of KEYTRUDA in KEYNOTE-048. Grade 3-5 all-cause adverse<br \/>\n      events occurred in 54.7%, 85.1% and 83.3% of patients in the KEYTRUDA<br \/>\n      monotherapy, KEYTRUDA in combination with chemotherapy and EXTREME<br \/>\n      regimen arms, respectively. Adverse events resulting in discontinuation<br \/>\n      occurred in 12.0%, 32.6% and 27.5% of patients in the KEYTRUDA<br \/>\n      monotherapy, KEYTRUDA in combination with chemotherapy and EXTREME<br \/>\n      regimen arms, respectively. Treatment-related deaths occurred in 1.0%,<br \/>\n      4.0% and 2.8% of patients in the KEYTRUDA monotherapy, KEYTRUDA in<br \/>\n      combination with chemotherapy and EXTREME regimen arms, respectively.<br \/>\n      Grade 3-5 immune-mediated or infusion reactions occurred in 7.0%, 5.4%<br \/>\n      and 10.5% of patients in the KEYTRUDA monotherapy, KEYTRUDA in<br \/>\n      combination with chemotherapy and EXTREME regimen arms, respectively.\n    <\/p>\n<p>\n      <b>Additional Information About KEYNOTE-048<\/b>\n    <\/p>\n<p>\n      KEYNOTE-048 enrolled 882 patients with recurrent or metastatic HNSCC who<br \/>\n      were randomized to one of three regimens as first-line therapy, as<br \/>\n      follows:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        KEYTRUDA monotherapy (200 mg fixed dosed every three weeks [Q3W]) for<br \/>\n        up to 24 months (n=301); or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        KEYTRUDA (200 mg fixed dose Q3W) in combination with cisplatin (100<br \/>\n        mg\/m<sup>2<\/sup> IV Q3W) or carboplatin (AUC 5 IV Q3W) plus 5-FU (1000<br \/>\n        mg\/m<sup>2<\/sup>\/day IV continuous from Day 1-4 Q3W (maximum six<br \/>\n        cycles), followed by additional KEYTRUDA monotherapy maintenance<br \/>\n        therapy until progression of disease, toxicity or until the patient<br \/>\n        had received a maximum of 24 months total treatment (n=281); or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        EXTREME regimen including cetuximab at a loading dose (400 mg\/m<sup>2<\/sup><br \/>\n        IV) followed by weekly doses (250 mg\/m<sup>2<\/sup> IV) in combination<br \/>\n        with cisplatin (100 mg\/m<sup>2<\/sup> IV Q3W) or carboplatin (AUC 5 IV<br \/>\n        Q3W) plus 5-FU (1000 mg\/m<sup>2<\/sup>\/day IV) continuous from Day 1-4<br \/>\n        Q3W (maximum six cycles), followed by additional cetuximab monotherapy<br \/>\n        maintenance therapy until progression of disease or toxicity (n=300).\n      <\/li>\n<\/ul>\n<p>\n      <b>About Head and Neck Cancer<\/b>\n    <\/p>\n<p>\n      Head and neck cancer describes a number of different tumors that develop<br \/>\n      in or around the throat, larynx, nose, sinuses and mouth. Most head and<br \/>\n      neck cancers are squamous cell carcinomas that begin in the flat,<br \/>\n      squamous cells that make up the thin surface layer of the structures in<br \/>\n      the head and neck. Two substances that greatly increase the risk of<br \/>\n      developing head and neck cancer are tobacco and alcohol. It is estimated<br \/>\n      that there were more than 887,000 new cases of head and neck cancer<br \/>\n      diagnosed and over 453,000 deaths from the disease worldwide in 2018. In<br \/>\n      the U.S. alone, it is estimated that there will be more than 65,000 new<br \/>\n      cases of head and neck cancer diagnosed and over 14,000 deaths from the<br \/>\n      disease in 2019.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection,<br \/>\n      100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n      program. There are currently more than 1,000 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Indications and<br \/>\n      Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma. The recommended dose of KEYTRUDA in patients with<br \/>\n      unresectable or metastatic melanoma is 200 mg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the adjuvant treatment of patients with<br \/>\n      melanoma with involvement of lymph node(s) following complete resection.<br \/>\n      The recommended dose of KEYTRUDA for the adjuvant treatment of adult<br \/>\n      patients with melanoma is 200 mg administered as an intravenous infusion<br \/>\n      over 30 minutes every three weeks until disease recurrence, unacceptable<br \/>\n      toxicity, or for up to 12 months in patients without disease recurrence.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is<br \/>\n      indicated for the first-line treatment of patients with metastatic<br \/>\n      nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK<br \/>\n      genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with carboplatin and either paclitaxel or<br \/>\n      paclitaxel protein-bound, is indicated for the first-line treatment of<br \/>\n      patients with metastatic squamous NSCLC.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with stage III NSCLC who are not candidates for surgical<br \/>\n      resection or definitive chemoradiation, or metastatic NSCLC, and whose<br \/>\n      tumors express PD-L1 [tumor proportion score (TPS) \u22651%] as determined by<br \/>\n      an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the treatment of patients<br \/>\n      with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined<br \/>\n      by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In NSCLC, the recommended dose of KEYTRUDA is 200 mg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for the chemotherapy agents<br \/>\n      administered in combination with KEYTRUDA, as appropriate.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA 200 mg<br \/>\n      is administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks until disease progression, unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after 3 or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA 200 mg is administered<br \/>\n      as an intravenous infusion over 30 minutes every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression. In pediatric patients with cHL,<br \/>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes at a<br \/>\n      dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Primary Mediastinal Large B-Cell Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory primary mediastinal large B-cell lymphoma (PMBCL), or<br \/>\n      who have relapsed after 2 or more prior lines of therapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in confirmatory trials. KEYTRUDA is not recommended for<br \/>\n      the treatment of patients with PMBCL who require urgent cytoreductive<br \/>\n      therapy.\n    <\/p>\n<p>\n      In adults with PMBCL, KEYTRUDA 200 mg is administered as an intravenous<br \/>\n      infusion over 30 minutes every three weeks until disease progression,<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with PMBCL, KEYTRUDA is administered<br \/>\n      as an intravenous infusion over 30 minutes at a dose of 2 mg\/kg (up to a<br \/>\n      maximum of 200 mg) every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who are not eligible<br \/>\n      for cisplatin-containing chemotherapy and whose tumors express PD-L1<br \/>\n      [combined positive score (CPS) \u226510] as determined by an FDA-approved<br \/>\n      test, or in patients who are not eligible for any platinum-containing<br \/>\n      chemotherapy regardless of PD-L1 status. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who have disease<br \/>\n      progression during or following platinum-containing chemotherapy or<br \/>\n      within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA 200 mg<br \/>\n      is administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks until disease progression or unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA 200 mg is administered as<br \/>\n      an intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression. In pediatric patients with MSI-H cancer,<br \/>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes at a<br \/>\n      dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS \u22651) as determined<br \/>\n      by an FDA-approved test, with disease progression on or after two or<br \/>\n      more prior lines of therapy including fluoropyrimidine- and<br \/>\n      platinum-containing chemotherapy and if appropriate, HER2\/neu-targeted<br \/>\n      therapy. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and durability of response. Continued approval for<br \/>\n      this indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA is 200 mg as an intravenous infusion over 30 minutes every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Cervical Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic cervical cancer with disease progression on or after<br \/>\n      chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n      FDA-approved test. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. The recommended dose of KEYTRUDA is 200 mg as an intravenous<br \/>\n      infusion over 30 minutes every three weeks until disease progression,<br \/>\n      unacceptable toxicity or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Hepatocellular Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with hepatocellular<br \/>\n      carcinoma (HCC) who have been previously treated with sorafenib. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA is 200 mg as an intravenous infusion over 30 minutes every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Merkel Cell Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with recurrent locally advanced or metastatic Merkel cell carcinoma.<br \/>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA in adults is 200 mg administered as an intravenous infusion<br \/>\n      over 30 minutes every three weeks until disease progression,<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. The recommended dose of KEYTRUDA in pediatric patients is 2<br \/>\n      mg\/kg (up to a maximum of 200 mg), administered as an intravenous<br \/>\n      infusion over 30 minutes every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Renal Cell Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, in combination with axitinib, is indicated for the first-line<br \/>\n      treatment of patients with advanced renal cell carcinoma. In renal cell<br \/>\n      carcinoma, KEYTRUDA 200 mg is administered as an intravenous infusion<br \/>\n      over 30 minutes every 3 weeks in combination with 5 mg axitinib orally<br \/>\n      twice daily until disease progression, unacceptable toxicity, or for<br \/>\n      KEYTRUDA, up to 24 months in patients without disease progression. When<br \/>\n      axitinib is used in combination with KEYTRUDA, dose escalation of<br \/>\n      axitinib above the initial 5 mg dose may be considered at intervals of<br \/>\n      six weeks or longer. See also the Prescribing Information for<br \/>\n      recommended axitinib dosing information.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA (pembrolizumab)<br \/>\n      Injection, 100mg<\/b>\n    <\/p>\n<p>\n      <b>Immune-Mediated Pneumonitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 3.4% (94\/2799) of patients with various cancers<br \/>\n      receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4<br \/>\n      (0.3%), and 5 (0.1%). Pneumonitis occurred in 8.2% (65\/790) of NSCLC<br \/>\n      patients receiving KEYTRUDA as a single agent, including Grades 3-4 in<br \/>\n      3.2% of patients, and occurred more frequently in patients with a<br \/>\n      history of prior thoracic radiation (17%) compared to those without<br \/>\n      (7.7%).\n    <\/p>\n<p>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Colitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7%<br \/>\n      (48\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%). Monitor patients for signs and symptoms of<br \/>\n      colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Hepatitis, or Hepatoxicity (in Combination With<br \/>\n      Axitinib)<\/b>\n    <\/p>\n<p>\n      <i>Immune-Mediated Hepatitis<\/i>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7%<br \/>\n      (19\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%). Monitor patients for changes in liver function.<br \/>\n      Administer corticosteroids for Grade 2 or greater hepatitis and, based<br \/>\n      on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <i>Hepatotoxicity (in Combination With Axitinib)<\/i>\n    <\/p>\n<p>\n      KEYTRUDA in combination with axitinib can cause hepatic toxicity with<br \/>\n      higher than expected frequencies of Grades 3 and 4 ALT and AST<br \/>\n      elevations compared to KEYTRUDA alone. Grades 3 and 4 increased ALT and<br \/>\n      AST were seen in 20% and 13% of patients, respectively. Monitor liver<br \/>\n      enzymes before initiation of and periodically throughout treatment.<br \/>\n      Consider more frequent monitoring of liver enzymes as compared to when<br \/>\n      the drugs are used in monotherapy. For elevated liver enzymes, interrupt<br \/>\n      KEYTRUDA and axitinib, and consider administering corticosteroids as<br \/>\n      needed.\n    <\/p>\n<p>\n      <b>Immune-Mediated Endocrinopathies<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis, thyroid disorders, and type 1 diabetes<br \/>\n      mellitus. Hypophysitis occurred in 0.6% (17\/2799) of patients, including<br \/>\n      Grade 2 (0.2%), 3 (0.3%), and 4 (&lt;0.1%). Hypothyroidism occurred in 8.5%<br \/>\n      (237\/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The<br \/>\n      incidence of new or worsening hypothyroidism was higher in patients with<br \/>\n      HNSCC, occurring in 15% (28\/192) of patients. Hyperthyroidism occurred<br \/>\n      in 3.4% (96\/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%),<br \/>\n      and thyroiditis occurred in 0.6% (16\/2799) of patients, including Grade<br \/>\n      2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis,<br \/>\n      occurred in 0.2% (6\/2799) of patients.\n    <\/p>\n<p>\n      Monitor patients for signs and symptoms of hypophysitis (including<br \/>\n      hypopituitarism and adrenal insufficiency), thyroid function (prior to<br \/>\n      and periodically during treatment), and hyperglycemia. For hypophysitis,<br \/>\n      administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2 and withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis. Administer hormone replacement for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes and<br \/>\n      withhold KEYTRUDA and administer antihyperglycemics in patients with<br \/>\n      severe hyperglycemia.\n    <\/p>\n<p>\n      <b>Immune-Mediated Nephritis and Renal Dysfunction<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3%<br \/>\n      (9\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Nephritis occurred in 1.7% (7\/405) of<br \/>\n      patients receiving KEYTRUDA in combination with pemetrexed and platinum<br \/>\n      chemotherapy. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Skin Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Other Immune-Mediated Adverse Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated adverse reactions, which may be severe or fatal, can<br \/>\n      occur in any organ system or tissue in patients receiving KEYTRUDA and<br \/>\n      may also occur after discontinuation of treatment. For suspected<br \/>\n      immune-mediated adverse reactions, ensure adequate evaluation to confirm<br \/>\n      etiology or exclude other causes. Based on the severity of the adverse<br \/>\n      reaction, withhold KEYTRUDA and administer corticosteroids. Upon<br \/>\n      improvement to Grade 1 or less, initiate corticosteroid taper and<br \/>\n      continue to taper over at least 1 month. Based on limited data from<br \/>\n      clinical studies in patients whose immune-related adverse reactions<br \/>\n      could not be controlled with corticosteroid use, administration of other<br \/>\n      systemic immunosuppressants can be considered. Resume KEYTRUDA when the<br \/>\n      adverse reaction remains at Grade 1 or less following corticosteroid<br \/>\n      taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated<br \/>\n      adverse reaction that recurs and for any life-threatening<br \/>\n      immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and<br \/>\n      encephalitis. In addition, myelitis and myocarditis were reported in<br \/>\n      other clinical trials, including classical Hodgkin lymphoma, and<br \/>\n      postmarketing use.\n    <\/p>\n<p>\n      Treatment with KEYTRUDA may increase the risk of rejection in solid<br \/>\n      organ transplant recipients. Consider the benefit of treatment vs the<br \/>\n      risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      <b>Infusion-Related Reactions<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 0.2% (6\/2799) of patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Complications of Allogeneic Hematopoietic Stem Cell Transplantation<br \/>\n      (HSCT)<\/b>\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of<br \/>\n      23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6<br \/>\n      (26%) developed graft-versus-host disease (GVHD) (1 fatal case) and 2<br \/>\n      (9%) developed severe hepatic veno-occlusive disease (VOD) after<br \/>\n      reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute<br \/>\n      GVHD after allogeneic HSCT have also been reported in patients with<br \/>\n      lymphoma who received a PD-1 receptor\u2013blocking antibody before<br \/>\n      transplantation. Follow patients closely for early evidence of<br \/>\n      transplant-related complications such as hyperacute graft-versus-host<br \/>\n      disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile<br \/>\n      syndrome, hepatic veno-occlusive disease (VOD), and other<br \/>\n      immune-mediated adverse reactions.\n    <\/p>\n<p>\n      In patients with a history of allogeneic HSCT, acute GVHD (including<br \/>\n      fatal GVHD) has been reported after treatment with KEYTRUDA. Patients<br \/>\n      who experienced GVHD after their transplant procedure may be at<br \/>\n      increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA<br \/>\n      vs the risk of GVHD in these patients.\n    <\/p>\n<p>\n      <b>Increased Mortality in Patients With Multiple Myeloma<\/b>\n    <\/p>\n<p>\n      In trials in patients with multiple myeloma, the addition of KEYTRUDA to<br \/>\n      a thalidomide analogue plus dexamethasone resulted in increased<br \/>\n      mortality. Treatment of these patients with a PD-1 or PD-L1 blocking<br \/>\n      antibody in this combination is not recommended outside of controlled<br \/>\n      trials.\n    <\/p>\n<p>\n      <b>Embryofetal Toxicity<\/b>\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. Advise women of this potential risk.<br \/>\n      In females of reproductive potential, verify pregnancy status prior to<br \/>\n      initiating KEYTRUDA and advise them to use effective contraception<br \/>\n      during treatment and for 4 months after the last dose.\n    <\/p>\n<p>\n      <b>Adverse Reactions<\/b>\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      permanent discontinuation in more than one patient were colitis (1.4%),<br \/>\n      autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy<br \/>\n      (0.4%), and cardiac failure (0.4%). The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and<br \/>\n      nausea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-054, KEYTRUDA was permanently discontinued due to adverse<br \/>\n      reactions in 14% of 509 patients; the most common (\u22651%) were pneumonitis<br \/>\n      (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions<br \/>\n      occurred in 25% of patients receiving KEYTRUDA. The most common adverse<br \/>\n      reaction (\u226520%) with KEYTRUDA was diarrhea (28%).\n    <\/p>\n<p>\n      In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and<br \/>\n      platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was<br \/>\n      discontinued due to adverse reactions in 20% of 405 patients. The most<br \/>\n      common adverse reactions resulting in permanent discontinuation of<br \/>\n      KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most<br \/>\n      common adverse reactions (\u226520%) with KEYTRUDA were nausea (56%), fatigue<br \/>\n      (56%), constipation (35%), diarrhea (31%), decreased appetite (28%),<br \/>\n      rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia<br \/>\n      (20%).\n    <\/p>\n<p>\n      In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and<br \/>\n      either paclitaxel or paclitaxel protein-bound in metastatic squamous<br \/>\n      NSCLC, KEYTRUDA was discontinued due to adverse reactions in 15% of 101<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were febrile neutropenia, pneumonia, and urinary<br \/>\n      tract infection. Adverse reactions observed in KEYNOTE-407 were similar<br \/>\n      to those observed in KEYNOTE-189 with the exception that increased<br \/>\n      incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs<br \/>\n      25%) were observed in the KEYTRUDA and chemotherapy arm compared to the<br \/>\n      placebo and chemotherapy arm in KEYNOTE-407.\n    <\/p>\n<p>\n      In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      19% of 636 patients; the most common were pneumonitis (3%), death due to<br \/>\n      unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious<br \/>\n      adverse reactions reported in at least 2% of patients were pneumonia<br \/>\n      (7%), pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural<br \/>\n      effusion (2.2%). The most common adverse reaction (\u226520%) was fatigue<br \/>\n      (25%).\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC; the most common<br \/>\n      was pneumonitis (1.8%). The most common adverse reactions (\u226520%) were<br \/>\n      decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (\u226520%) were fatigue, decreased appetite, and dyspnea.<br \/>\n      Adverse reactions occurring in patients with HNSCC were generally<br \/>\n      similar to those occurring in patients with melanoma or NSCLC who<br \/>\n      received KEYTRUDA as a monotherapy, with the exception of increased<br \/>\n      incidences of facial edema and new or worsening hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL. Serious adverse reactions occurred in 16% of<br \/>\n      patients; those \u22651% included pneumonia, pneumonitis, pyrexia, dyspnea,<br \/>\n      GVHD, and herpes zoster. Two patients died from causes other than<br \/>\n      disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1<br \/>\n      from septic shock. The most common adverse reactions (\u226520%) were fatigue<br \/>\n      (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea<br \/>\n      (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of<br \/>\n      patients and included arrhythmia (4%), cardiac tamponade (2%),<br \/>\n      myocardial infarction (2%), pericardial effusion (2%), and pericarditis<br \/>\n      (2%). Six (11%) patients died within 30 days of start of treatment. The<br \/>\n      most common adverse reactions (\u226520%) were musculoskeletal pain (30%),<br \/>\n      upper respiratory tract infection and pyrexia (28% each), cough (26%),<br \/>\n      fatigue (23%), and dyspnea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. Serious adverse reactions occurred in 42% of patients; those<br \/>\n      \u22652% were urinary tract infection, hematuria, acute kidney injury,<br \/>\n      pneumonia, and urosepsis. The most common adverse reactions (\u226520%) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse<br \/>\n      reactions occurred in 39% of KEYTRUDA-treated patients; those \u22652% were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis. The most<br \/>\n      common adverse reactions (\u226520%) in patients who received KEYTRUDA were<br \/>\n      fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased<br \/>\n      appetite (21%), nausea (21%), and rash (20%).\n    <\/p>\n<p>\n      Adverse reactions occurring in patients with gastric cancer were similar<br \/>\n      to those occurring in patients with melanoma or NSCLC who received<br \/>\n      KEYTRUDA as a monotherapy.\n    <\/p>\n<p>\n      In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 98 patients with recurrent or metastatic cervical cancer. Serious<br \/>\n      adverse reactions occurred in 39% of patients receiving KEYTRUDA; the<br \/>\n      most frequent included anemia (7%), fistula, hemorrhage, and infections<br \/>\n      [except urinary tract infections] (4.1% each). The most common adverse<br \/>\n      reactions (\u226520%) were fatigue (43%), musculoskeletal pain (27%),<br \/>\n      diarrhea (23%), pain and abdominal pain (22% each), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      Adverse reactions occurring in patients with HCC were generally similar<br \/>\n      to those in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n      monotherapy, with the exception of increased incidences of ascites (8%<br \/>\n      Grades 3-4) and immune-mediated hepatitis (2.9%). Laboratory<br \/>\n      abnormalities (Grades 3-4) that occurred at a higher incidence were<br \/>\n      elevated AST (20%), ALT (9%), and hyperbilirubinemia (10%).\n    <\/p>\n<p>\n      Among the 50 patients with MCC enrolled in study KEYNOTE-017, adverse<br \/>\n      reactions occurring in patients with MCC were generally similar to those<br \/>\n      occurring in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n      monotherapy. Laboratory abnormalities (Grades 3-4) that occurred at a<br \/>\n      higher incidence were elevated AST (11%) and hyperglycemia (19%).\n    <\/p>\n<p>\n      KEYNOTE-426, when KEYTRUDA was administered in combination with<br \/>\n      axitinib, fatal adverse reactions occurred in 3.3% of 429 patients.<br \/>\n      Serious adverse reactions occurred in 40% of patients, the most frequent<br \/>\n      of which (\u22651%) included hepatotoxicity (7%), diarrhea (4.2%), acute<br \/>\n      kidney injury (2.3%), dehydration (1%), and pneumonitis (1%).\n    <\/p>\n<p>\n      Permanent discontinuation due to an adverse reaction occurred in 31% of<br \/>\n      patients; KEYTRUDA only (13%), axitinib only (13%), and the combination<br \/>\n      (8%). The most common adverse reactions (&gt;1%) resulting in permanent<br \/>\n      discontinuation of KEYTRUDA, axitinib, or the combination were<br \/>\n      hepatotoxicity (13%), diarrhea\/colitis (1.9%), acute kidney injury<br \/>\n      (1.6%), and cerebrovascular accident (1.2%).\n    <\/p>\n<p>\n      When KEYTRUDA was used in combination with axitinib, the most common<br \/>\n      adverse reactions (\u226520%) were diarrhea (56%), fatigue\/asthenia (52%),<br \/>\n      hypertension (48%), hepatotoxicity (39%), hypothyroidism (35%),<br \/>\n      decreased appetite (30%), palmar-plantar erythrodysesthesia (28%),<br \/>\n      nausea (28%), stomatitis\/mucosal inflammation (27%), dysphonia (25%),<br \/>\n      rash (25%), cough (21%), and constipation (21%).\n    <\/p>\n<p>\n      <b>Lactation<\/b>\n    <\/p>\n<p>\n      Because of the potential for serious adverse reactions in breastfed<br \/>\n      children, advise women not to breastfeed during treatment and for 4<br \/>\n      months after the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use<\/b>\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a trial, 40<br \/>\n      pediatric patients (16 children aged 2 years to younger than 12 years<br \/>\n      and 24 adolescents aged 12 years to 18 years) with various cancers,<br \/>\n      including unapproved usages, were administered KEYTRUDA 2 mg\/kg every 3<br \/>\n      weeks. Patients received KEYTRUDA for a median of 3 doses (range 1\u201317<br \/>\n      doses), with 34 patients (85%) receiving 2 doses or more. The safety<br \/>\n      profile in these pediatric patients was similar to that seen in adults;<br \/>\n      adverse reactions that occurred at a higher rate (\u226515% difference) in<br \/>\n      these patients when compared to adults under 65 years of age were<br \/>\n      fatigue (45%), vomiting (38%), abdominal pain (28%), increased<br \/>\n      transaminases (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment. As<br \/>\n      part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers. For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2018 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a><br \/>\n<span class=\"bwuline\">)<\/span>.\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA at <\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n      <b>and Medication Guide for KEYTRUDA at <\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele<br \/>(267) 305-3558<br \/>or<br \/>Ayn Wisler<br \/>(908)        740-5590     <\/p>\n<p>       Investors:<br \/>Teri Loxam<br \/>(908) 740-1986<br \/>or<br \/>Peter        Dannenbaum<br \/>(908) 740-1037     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the final analysis of the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck\u2019s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy, for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #6000). Data include the first-time presentation of certain overall survival (OS) hypotheses from the KEYTRUDA in combination with chemotherapy study arm based on PD-L1 expression and the KEYTRUDA monotherapy study arm in the total patient population. Results of an interim analysis were presented at the European Society for Medical Oncology (ESMO) 2018 Congress and demonstrated superior OS outcomes for KEYTRUDA in combination with chemotherapy in the total population and KEYTRUDA monotherapy in patients whose tumors expressed<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289,56],"class_list":["post-746030","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the final analysis of the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck\u2019s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy, for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #6000). Data include the first-time presentation of certain overall survival (OS) hypotheses from the KEYTRUDA in combination with chemotherapy study arm based on PD-L1 expression and the KEYTRUDA monotherapy study arm in the total patient population. Results of an interim analysis were presented at the European Society for Medical Oncology (ESMO) 2018 Congress and demonstrated superior OS outcomes for KEYTRUDA in combination with chemotherapy in the total population and KEYTRUDA monotherapy in patients whose tumors expressed\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"30 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\\\/\",\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-05-31T05:45:00+00:00\",\"dateModified\":\"2025-05-12T12:58:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the final analysis of the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck\u2019s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy, for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #6000). Data include the first-time presentation of certain overall survival (OS) hypotheses from the KEYTRUDA in combination with chemotherapy study arm based on PD-L1 expression and the KEYTRUDA monotherapy study arm in the total patient population. Results of an interim analysis were presented at the European Society for Medical Oncology (ESMO) 2018 Congress and demonstrated superior OS outcomes for KEYTRUDA in combination with chemotherapy in the total population and KEYTRUDA monotherapy in patients whose tumors expressed","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:05+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"30 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/","name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-05-31T05:45:00+00:00","dateModified":"2025-05-12T12:58:05+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"7c4f72f5-13a2-431c-8fc5-7f4da1a42de4","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-KEYTRUDA-pembrolizumab-Demonstrates-Improved-Overall-Survival-as-First-Line-Treatment-of-Recurrent-or-Metastatic-Head-and-Neck-P9SHF.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746030\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746030"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}